Compare ASE Technology Holding Co Ltd (ASX) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs BridgeBio Pharma Inc — how do they compare? ASE Technology Holding Co Ltd trades at $39.05 (market cap $101.68B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: ASE Technology Holding Co Ltd is far larger — about 6.1× BridgeBio Pharma Inc's market cap, and ASE Technology Holding Co Ltd pays a 1.11% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| ASX | BBIO | |
|---|---|---|
Market Cap | $101.68B | $16.61B |
Sector | Technology | Health |
52-Week High | $45.12 | $90.17 |
52-Week Low | $9.63 | $47.29 |
Enterprise Value | $106.08B | $18.16B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $37.39, up 0.38% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.29, beating estimates of $0.23, and announced a $10.5 billion capital expenditure increase for AI-driven growth (Reuters, July 30, 2026). Revenue rose to $645.39 billion in 2025, with net income of $40.02 billion, while valuation ratios like P/E of 46.26 suggest premium pricing.
Outlook remains positive due to AI semiconductor demand and margin expansion, but risks include high valuation and competitive pressures. Analysts are largely bullish with 80% buy ratings, though the stock faces volatility near resistance at $38.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
